We are live on ! Find out more
AVTX icon

Avalo Therapeutics
AVTX

84 hedge funds and large institutions have $361M invested in Avalo Therapeutics in 2025 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 28 increasing their positions, 13 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

120% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 15

115% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 13

85% more capital invested

Capital invested by funds: $195M → $361M (+$166M)

81% more call options, than puts

Call options by funds: $6.05M | Put options by funds: $3.35M

27% more funds holding

Funds holding: 66 → 84 (+18)

6.8% less ownership

Funds ownership: 116.46% → 109.66% (-6.8%)

Holders
84
Holders Change
+18
Holders Change %
+27.27%
% of All Funds
1.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
33
Increased
28
Reduced
13
Closed
15
Calls
$6.05M
Puts
$3.35M
Net Calls
+$2.7M
Net Calls Change
+$1.97M

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$8.82M
2
Jennison Associates
Jennison Associates
New York
+$8.03M
3
Marshall Wace
Marshall Wace
United Kingdom
+$7.62M
4
SCM
Soleus Capital Management
Connecticut
+$7.46M
5
UBS Group
UBS Group
Switzerland
+$7.3M

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$7.2M
2
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$6.38M
3
SCM
Silverarc Capital Management
Massachusetts
-$3.32M
4
O
OrbiMed
New York
-$2.73M
5
ABG
Ally Bridge Group
New York
-$2.26M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
26
Fidelity Investments
Massachusetts
$4M +$3.72M +220,300 New
Ameriprise
27
Ameriprise
Minnesota
$3.96M +$74.3K +4,402 +2%
JG
28
Jain Global
New York
$3.95M +$3.67M +217,292 New
Susquehanna International Group
29
Susquehanna International Group
Pennsylvania
$3.83M +$2.76M +163,596 +345%
BFM
30
Boothbay Fund Management
New York
$3.67M -$442K -26,170 -11%
BNP Paribas Financial Markets
31
BNP Paribas Financial Markets
France
$3.59M +$3.34M +197,742 +3,954,840%
SC
32
SummitTX Capital
Texas
$3.56M +$3.31M +195,873 New
NFT
33
Nan Fung Trinity
Hong Kong
$3.43M +$3.19M +189,000 New
Jane Street
34
Jane Street
New York
$3.25M +$3.02M +178,855 New
Geode Capital Management
35
Geode Capital Management
Massachusetts
$3.02M +$1.05M +61,963 +59%
SCM
36
Superstring Capital Management
New York
$2.78M -$587K -34,767 -18%
Deutsche Bank
37
Deutsche Bank
Germany
$2.72M +$2.53M +150,000 New
Two Sigma Investments
38
Two Sigma Investments
New York
$2.69M +$1.67M +98,995 +201%
PA
39
Perceptive Advisors
New York
$2.54M – – –
SC
40
Stempoint Capital
New York
$2.46M +$2.29M +135,552 New
MAP
41
Moody Aldrich Partners
Massachusetts
$2.42M +$2.25M +133,231 New
SCM
42
Squadron Capital Management
Illinois
$2.36M +$2.19M +130,000 New
GPP
43
Great Point Partners
Connecticut
$2.26M +$2.1M +124,666 New
Barclays
44
Barclays
United Kingdom
$1.92M +$1.63M +96,468 +1,032%
HS
45
HighVista Strategies
Massachusetts
$1.74M +$1.15M +67,853 +244%
Aberdeen Group
46
Aberdeen Group
United Kingdom
$1.73M +$382K +22,626 +31%
FAM
47
Fred Alger Management
New York
$1.45M +$1.35M +80,092 New
State Street
48
State Street
Massachusetts
$1.44M +$570K +33,800 +74%
SCM
49
Sio Capital Management
New York
$1.31M – – –
Goldman Sachs
50
Goldman Sachs
New York
$1.19M +$1.1M +65,313 New
1
2
3 4

AVTX Hedge Fund Activity: Q4 2025 in Review

84 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q4 2025, worth a combined $361M — up 85% from $195M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new AVTX positions and 15 closed out — a net gain of 18 holders — while 28 added to existing stakes and 13 trimmed.

The largest buyer was Millennium Management, adding an estimated $8.82M. The largest seller was Point72 Asset Management, cutting an estimated $7.2M.

  • 84 institutional investors held Avalo Therapeutics (AVTX) as of Q4 2025, up from 66 in Q3 2025.
  • Funds reported $361M of Avalo Therapeutics stock for Q4 2025, up 85% quarter-over-quarter.
  • 33 funds opened new Avalo Therapeutics positions in Q4 2025 and 15 closed out, a net change of +18 holders.
  • The largest Avalo Therapeutics buyer in Q4 2025 was Millennium Management, an estimated $8.82M added.
  • The largest Avalo Therapeutics seller in Q4 2025 was Point72 Asset Management, an estimated $7.2M sold.

Based on aggregated 13F filings for Q4 2025.